Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes ...

Akeso has won the FDA’s go-ahead for its PD-1 inhibitor penpulimab co-developed with Sino Biopharmaceutical’s Chia Tai-Tianqing Pharmaceutical. To be marked as Anniko, penpulimab is approved ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for advanced squamous cell carcinoma of the anal canal (SCAC), although ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...

Hong Kong's Akeso has ended the week on a high note, with an FDA approval for its PD-1 inhibitor penpulimab and more data on PD-1/VEGF bispecific antibody ivonescimab. Penpulimab has picked up a ...

Full results from the trial evaluating Akeso’s first-in-class PD-1/VEGF bispecific antibody are expected to be presented later this year at a medical conference. 1 "The interim analysis results from ...

The FDA has approved Akeso’s penpulimab-kcqx, a PD-1 monoclonal antibody, for two indications treating nasopharyngeal carcinoma (NPC). The drug is now indicated in combination with chemotherapy as a ...

Sensei Biotherapeutics reports promising clinical data in PD-(L)1-resistant cancer patients, with cash to fund operations through Q2 2026. Sensei Biotherapeutics, Inc. announced promising clinical ...

HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with ...

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...